StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) stock

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.81+0.01 (+1.06%)

Close on Nov 17, 2026Market cap $104.43MP/E –Yield –

Earnings

Organogenesis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$45.50M
-69.8% on a year earlier
EPS, Q3 FY2026
-$0.25
$0.11 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Organogenesis's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$45.50M-69.8%-$0.25Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$42.80M-57.5%-$0.77Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours$36.30M-58.1%-$0.44Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours$225.61M+78.1%–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$150.50M+30.6%$0.11Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$100.80M-22.6%-$0.10Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$86.70M-21.2%–Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours$126.70M+27.1%–Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours$115.20M+6.2%$0.09Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$130.20M+11.0%-$0.13Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$110.00M+2.2%-$0.02Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Organogenesis's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total net revenueFY2026$179.40M – $200.00M–NewNov 5, 2026
Total net revenueFY2026$179.00M – $215.00M$270.00M – $310.00MLoweredAug 6, 2026
Total net revenue declineFY2026-52% – -45%-38% – -25%LoweredMay 7, 2026

Guidance vs results

The last range Organogenesis gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$500.00M – $525.00M$563.61MΣ4QAbove range
FY2025Revenue growth+4% – +9%+16.91%Σ4QAbove range

Guidance history

Every forecast Organogenesis put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Total net revenueFY2026$179.40M – $200.00MNew
Aug 6, 2026Total net revenueFY2026$179.00M – $215.00MLowered
May 7, 2026Total net revenueFY2026$270.00M – $310.00MLowered
May 7, 2026Total net revenue declineFY2026-52% – -45%Lowered
Feb 26, 2026Total net revenueFY2026$350.00M – $420.00MNew
Feb 26, 2026Total net revenue declineFY2026-38% – -25%New
Nov 6, 2025EBITDAFY2025$19.10M – $41.90MNew
Nov 6, 2025Adjusted EBITDAFY2025$45.50M – $68.30MRaised
Nov 6, 2025Net product revenue from Advanced Wound Care productsFY2025+4% – +8%New
Nov 6, 2025Net product revenue from Surgical & Sports Medicine productsFY2025+6% – +23%Raised
Nov 6, 2025Net product revenue from Advanced Wound Care productsFY2025$470.00M – $490.00MNew
Nov 6, 2025Net product revenue from Surgical & Sports Medicine productsFY2025$30.00M – $35.00MLowered
Nov 6, 2025Net incomeFY2025$8.60M – $25.40MNew
Nov 6, 2025adjusted net incomeFY2025$21.50M – $38.40MNew
Nov 6, 2025Net product revenueFY2025+4% – +9%New
Nov 6, 2025Net product revenueFY2025$500.00M – $525.00MNew
Aug 7, 2025EBITDAFY2025$6.20M – $37.00MNew
Aug 7, 2025Adjusted EBITDAFY2025$31.10M – $61.90MLowered
Aug 7, 2025Net income (loss)FY2025-$6.40M – $16.40MLowered
Aug 7, 2025adjusted net incomeFY2025$5.50M – $28.30MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Organogenesis filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. Results
  10. Update
  11. Results
  12. News
  13. News
  14. Results
  15. Results

See a number that looks wrong?